13-14 January 2027 | Amsterdam, Netherlands

www.rational-based-drug-design-europe.com

SAVE UP TO €330 BY REGISTERING BEFORE 13 NOVEMBER

Rational Based Drug Design Summit EUROPE

Driving Safer, Faster & More Efficient Discovery Across Europe

Integrating Structural Insights, Orthogonal Biophysics & AI to Accelerate Discovery of Novel Targets & De-Risk Candidate Development Across Europe

Expert Speakers Include:



Alexey Rak
Head of Bio Structure & Biophysics
Sanofi



Ilaria Ferlenghi
Associate Director, Senior Scientific Leader Protein Structure & Biochemistry, Vx Discovery Tech
GSK



Ansgar Wegener
Director Structural Biology & Biophysics
Merck Healthcare



Jonathan Hopper
Founder & Vice President, Platforms
OMass Therapeutics



Taiana Maia de Oliveira
Director, Biophysics
AstraZeneca



Pravin Mahajan
Associate Director, Discovery Technologies
Astex Pharmaceuticals

+44 20 3141 8700 info@hansonwade.com
www.rational-based-drug-design-europe.com

hansonwade

Europe's Industry-Dedicated Forum to Accelerate & De-Risk Rational Drug Design

Rational Based Drug Design Summit EUROPE

13-14 January 2027 | Amsterdam, NE

With recent breakthroughs in AI and structural biology transforming how biopharma companies design and optimise drugs, the boundaries between medicinal chemistry, structural biology, biophysics, and computational chemistry are evolving. As a result, new, integrated approaches to drug discovery are needed.

The inaugural **Rational Drug Design Europe Summit** has arrived to unite experts at Europe's dedicated meeting to explore how cutting-edge technologies are transforming the early drug discovery process and enabling scientists to tackle increasingly complex targets with greater precision.

This is the **one-stop shop for Europe's drug discovery community**, with two days of presentations and networking designed to help you stay at the forefront of rational drug design, including:

- **Bridging the Gap:** Merging experimental data and computational predictions with AI and machine learning to accelerate decision-making and enhance prediction accuracy.
- **Accelerating the DMTA Cycle:** Integrating novel biophysical and structural methods to speed up the 'design-make-test-analyse' cycle.
- **Tackling New Targets:** Harnessing the latest technology advancements to elucidate structures of challenging targets.
- **Case Studies:** Learning from real-world applications and case studies on how to successfully implement a rational drug design strategy in your projects.
- **New Modalities:** Exploring the power of rational drug design across small molecules, biologics, and emerging modalities like PROTACs and molecular glues.

Don't miss the opportunity to unite with your dedicated community in Europe and unlock the potential of rational drug design to help shape the future of drug discovery.

70+ Drug Design Experts

20+ Scientific Sessions

7 Hours of Dedicated Networking

2 Days of Scientific Content

1 Epicentre of Drug Design



+44 20 3141 8700 info@hansonwade.com
www.rational-based-drug-design-europe.com

hansonwade

What to Expect in 2027

Unmissable Sessions



Ilaria Ferlenghi, Associate Director, Senior Scientific Leader Protein Structure & Biochemistry, Vx Discovery Tech, **GSK**

With increasing pressure to improve productivity while reducing development risk, the ability to integrate diverse datasets into actionable drug discovery decisions has never been more critical. Join Ilaria Ferlenghi as she explores how leading discovery teams are combining structural biology, biophysics, computational modelling and AI to identify higher-quality candidates earlier, accelerate progression through the pipeline, and increase confidence in decision-making.

1



Taiana Maia de Oliveira, Director, Biophysics, **AstraZeneca**

Cryo-EM is transforming structure-enabled drug discovery, providing unprecedented access to complex targets that were previously beyond reach. Learn how Taiana advances in cryo-EM are enabling organisations to generate high-resolution structural insights faster, overcome traditional crystallography limitations, and dramatically expand the range of tractable targets available for therapeutic intervention.

2

Companies attending in 2027

GSK · AstraZeneca · OMass Therapeutics · Merck · sanofi · bicycle therapeutics

Integrated Structured & Spontaneous Networking Sessions:

Speed Networking & Networking Breaks

Over six hours dedicated to sparking new connections that last well beyond the summit.

Roundtables & Panels

Engage with peers on open and candid discussions on the latest challenges, innovations, and opportunities.

Poster Session

Showcase emerging research, new technologies and innovative approaches, and hear immediate feedback from fellow attendees, researchers, and potential collaborators.

+44 20 3141 8700 info@hansonwade.com
www.rational-based-drug-design-europe.com
hansonwade

Your Expert Speakers

Pharma Rational Design Leaders:



Alexey Rak
Head of Bio Structure & Biophysics
Sanofi



Ilaria Ferlenghi
Associate Director, Senior Scientific Leader Protein Structure & Biochemistry, Vx Discovery Tech
GSK



Ansgar Wegener
Director, Structural Biology & Biophysics
Merck Healthcare



Taiana Maia de Oliveira
Director, Biophysics
AstraZeneca



Alain Beck
Senior Director, Biologics CMC & Developability
Pierre Fabre



Felix Metzner
Structural Research
Boehringer Ingelheim

European Biotech Discovery Innovators:



Robert Dagil
Director, Bispecific Antibodies & CMC
VAR2 Pharmaceuticals



Jonathan Hopper
Founder & Vice President, Platforms
OMass Therapeutics



Pravin Mahajan
Associate Director, Discovery Technologies
Astex Pharmaceuticals



Beatrice Li
Team Lead of Protein Science & Structural Biology
Confo Therapeutics



Gustavo Arruda Bezerra
Associate Director, Structural Biology
Bicycle Therapeutics



Klaus Orlinger
Chief Scientific Officer
VALANX Biotech



Kirill Pevzner
Founder & Chief Technical Officer
Protai



Victor Guallar
ICREA Professor & Group Leader
Barcelona Supercomputing Group



Christian Ottmann
Founder & Chief Executive Officer
Ambagon Therapeutics



Krzysztof Brzózka
Chief Scientific Officer
Ryvu Therapeutics



David Brown
Senior Director Structural Biology and Biophysics
Vertex Pharmaceuticals



Radoslav Enchev
Group Leader
The Francis Crick Institute



Björn Schwalb
Chief AI & Data Officer
NEOsphere Biotechnologies

> The networking was great. The topics were very useful. I came away with some very specific ideas for what I'm going to try in the lab right away for troubleshooting. I was especially interested in learning about how other companies and biophysics groups are using and incorporating AI into their workflows.
>
> **UCB, Biophysics for Drug Discovery Summit Attendee**

Conference Day One
Wednesday 13th January, 2027

8.00 **Check In, Morning Coffee & Light Refreshments**



Beatrice Li
Team Lead of Protein Science & Structural Biology
Confo Therapeutics

8.40 **Chair's Opening Remarks**

Unlocking the Next Generation of Therapeutics: Harnessing Structural Biology, Biophysics & AI to Expand the Druggable Universe & Reduce Discovery Risk

8.45 **Panel Discussion: Expanding the Druggable Universe & the Future of Rational Drug Design in an Era of AI, Structural Biology & Emerging Modalities**

- Explore why complex, dynamic, and previously inaccessible targets have challenged traditional drug discovery approaches
- Discover how advances in structural biology, biophysics, computational chemistry, and AI are expanding the druggable proteome
- Understand how molecular glues, degraders, and other emerging modalities are reshaping discovery portfolios and required capabilities
- Identify which technologies are driving value today versus those likely to transform discovery over the next decade
- Learn how leading organisations are combining experimental and computational approaches to pursue challenging targets with greater confidence



Kirill Pevzner
Founder & Chief Technical Officer
Protai



David Brown
Senior Director Structural Biology and Biophysics
Vertex Pharmaceuticals



Jonathan Hopper
Founder & Vice President, Platforms
OMass Therapeutics



Ilaria Ferlenghi
Associate Director, Senior Scientific Leader Protein Structure & Biochemistry, Vx Discovery Tech
GSK



Alexey Rak
Head of Bio Structure & Biophysics
Sanofi

9.30 **Harnessing Generative & Agentic AI to Accelerate Structural Biology & Rational Drug Design**



Alexey Rak
Head of Bio Structure & Biophysics
Sanofi

- Explore the two-way interplay between generative AI and structural biology, leveraging AI to accelerate experimental structure determination while using structural data and metadata to improve predictive models
- Unlock new opportunities for rational drug design, from *de novo* biologics and novel small-molecule binding sites to improved target and mechanism-of-action identification
- Harness agentic AI to transform structural biology workflows, reducing data processing and acquisition times while streamlining sample preparation and increasing experimental productivity

10.00 **Speed Networking Session & Morning Break**

Join our Speed Networking Session for a series of focused introductions with fellow experts across computational chemistry, structural biology, AI, biophysics, and discovery research. In this dedicated structured networking session, exchange ideas, identify potential collaborators, and build valuable relationships that can accelerate your work long after the conference ends.

Bridging Structural Insights to Clinical Success by Improving Translation, Reducing Attrition & Increasing Confidence in Development Candidates

11.00 **Designing Effective Assay Cascades: From Hits to Validated Starting Points**



Ansgar Wegener
Director, Structural Biology & Biophysics
Merck Healthcare

- Learn how to design efficient screening and assay cascades integrating pharmacological, biophysical, and early ADME data to progress compounds from primary hit discovery through secondary validation and identify high-quality starting points
- Understand how structural biology and biophysics inform hit discovery strategy, assay selection, and hit triage, ensuring resources are focused on the compounds with the highest likelihood of success

Conference Day One
Wednesday 13th January, 2027



Robert Dagil
Director, Bispecific Antibodies & CMC
VAR2 Pharmaceuticals

11.30 **Advancing Rationally Designed Antibody Leads into Development Candidates Through Structural Validation & Translational Characterisation**

- Leverage phage display, structural biology and Cryo-EM to identify, characterise and down-select antibody leads against novel pan-cancer target onco-fetal chondroitin sulfate
- Integrate target biology, binding characterisation and *in vivo* localisation studies to prioritise candidates with the greatest translational potential
- Optimise pharmacokinetic profile using structural biology and functional datasets to de-risk candidate selection and increase confidence in progression toward clinical development

12.00 **Lunch & Networking**

Advancing High-Quality Leads into Development Candidates to Reduce Attrition Risk & Increase Clinical Success



Jonathan Hopper
Founder & Vice President, Platforms
OMass Therapeutics

1.00 **Combining Native Mass Spectrometry & Structural Approaches to Drive Early Compound Discovery**

- Native mass spectrometry can be utilized as a high-throughput screen which generates a rich and unique dataset during screening campaigns
- Complementary techniques, such as HDX, allow functional hits to be predicted by monitoring changes in conformational dynamics. These predictions show good translation into established cellular assays
- The combination of data provides a deeper understanding of structure-activity relationships ahead of initiating medicinal chemistry campaigns



Björn Schwalb
Chief AI & Data Officer
NEOsphere Biotechnologies

1.30 **Proteomics Driven AI/ML Powers Rational Molecular Glue Degrader Design**

- Introducing sphereOME: Leveraging deep proteomic and interactomic profiling of nearly 10,000 molecular glue degraders to map the accessible CRBN neosubstrate space across 11,000 proteins
- Harnessing sphereAI for rational degrader design: Learning the chemical features that drive selective degradation and predicting degradation potential for compound-target pairs, including targets without known degron motifs
- Closing the design loop with AI-driven optimization: Using reinforcement learning to generate novel degrader candidates that balance on-target efficacy with minimized off-target risk and improved selectivity profiles



Klaus Orlinger
Chief Science Officer
VALANX Biotech

2.00 **Rationally Designing Next-Generation ADCs Through Structural Biology, Computational Modelling & Site-Specific Conjugation**

- Leverage structural modelling to identify optimal antibody conjugation sites, improving ADC stability, payload delivery, and therapeutic performance while reducing empirical design cycles
- Integrate computational modelling and bioinformatics workflows to guide ADC design decisions, accelerate candidate selection, and increase confidence in lead optimisation strategies
- Demonstrate how rational, site-specific ADC engineering translates into improved efficacy and therapeutic index through real-world case studies linking structural insights to preclinical outcomes

2.30 **Afternoon Break & Scientific Poster Session**

The scientific poster session is your prime opportunity to showcase your discovery research and benchmark your results against the attending European discovery community. Make sure to use this time to visit the poster displays, speak to authors, and ask questions to collaborate and uncover the cutting edge of drug discovery innovation.

Conference Day One
Wednesday 13th January, 2027

Deploying AI & Machine Learning Strategically to Improve Prediction Accuracy, Accelerate Decision-Making & Deliver Measurable Discovery Impact

3.30 **Panel Discussion: Building Trust in AI Predictions by Validation & Benchmarking**

- Establish rigorous validation frameworks that identify the 50% of AI outputs that are hallucinations, ensuring your teams trust and adopt computational tools rather than dismissing them due to poor early experiences
- Learn how to benchmark AI predictions against experimental data, understanding which use cases deliver value and which remain aspirational
- Discover strategies to educate scientific teams on AI capabilities and limitations, setting realistic expectations and driving productive adoption while avoiding the "magic bullet" trap



Alain Beck
Senior Director Biologics CMC & Developability
Pierre Fabre



Beatrice Li
Team Lead of Protein Science & Structural Biology
Confo Therapeutics



Kirill Pevzner
Founder & Chief Technical Officer
Protai



Radoslav Enchev
Group Leader
The Francis Crick Institute

4.00 **Revealing Cryptic Binding Pockets Through High-Throughput Cryo-EM to Unlock Novel Drug Discovery Opportunities**

- Demonstrate how high-throughput cryo-EM captures transient protein conformations and protein-protein interactions in solution to reveal cryptic and previously inaccessible druggable pockets
- Integrate structural visualization with computational design workflows to identify, optimize, and experimentally validate novel molecules targeting rare functional protein states
- Explore how iterative structure generation and validation can create differentiated datasets to power next-generation AI models capable of predicting protein dynamics and accelerating rational drug discovery

4.30 **Roundtable Discussion: Which Technologies Are Delivering the Greatest Impact on Rational Drug Design Today?**

Close out Day One with an open, peer-led discussion exploring the breakthroughs, bottlenecks, and opportunities shaping the future of rational drug design. Exchange perspectives with fellow experts, challenge assumptions, and uncover actionable ideas that can help accelerate smarter, faster, and more confident drug discovery.

- Debate the relative impact of AI, structural biology, biophysics, medicinal chemistry, and computational modelling on accelerating discovery success
- Share lessons learned from integrating experimental and computational approaches to improve confidence in drug design decisions
- Identify the biggest barriers preventing organisations from fully realising the value of next-generation drug discovery technologies
- Discuss which capabilities, platforms, and skillsets teams should prioritise to stay competitive over the next five years



Krzysztof Brzózka
Chief Scientific Officer
Ryvu Therapeutics



David Brown
Senior Director Structural Biology and Biophysics
Vertex Pharmaceuticals



Beatrice Li
Team Lead of Protein Science & Structural Biology
Confo Therapeutics

5.00 **Chairs Closing Remarks**

5.10 **End of Conference Day One**

Conference Day Two
Thursday 14th January, 2027

8.00 **Check In, Morning Coffee & Light Refreshments**



Beatrice Li
Team Lead of Protein Science & Structural Biology
Confo Therapeutics

8.50 **Chair's Opening Remarks**

Integrating Computational Predictions & Experimental Validation to Prioritise High-Confidence Drug Design Decisions



Ilaria Ferlenghi
Associate Director, Senior Scientific Leader Protein Structure & Biochemistry, Vx Discovery Tech
GSK

9.00 **Combining Structural Biology, Biophysics & AI to Create Better Therapeutics Faster**

- Integrate structural, biophysical, and computational data to improve decision-making and accelerate candidate progression
- Leverage AI-powered predictions alongside experimental validation to identify high-quality drug candidates with greater confidence
- Discover how leading organisations are reducing discovery timelines by combining orthogonal technologies across the drug design process



Gustavo Arruda Bezerra
Associate Director, Structural Biology
Bicycle Therapeutics

9.30 **Integrating Next-Generation Structure Prediction Models to Improve Molecular Design Decisions & Increase Confidence in Experimental Success**

- Implement AlphaFold3, Boltz2, Chai, and Atheris for protein-ligand complex prediction, understanding when predictions are reliable versus when experimental validation is essential and navigating the landscape of available models
- Learn how to integrate predictions from evolutionary models, atomic foundational models, and FEP-based approaches, selecting the right tool for your specific application and avoiding naive implementation that wastes resources
- Understand the current limitations of AI-designed molecules and realistic timelines to first AI-derived drugs, managing leadership expectations while capitalising on genuine opportunities and addressing the critical data gap

10.00 **Morning Break & Networking**

Accelerating Structure Determination with Next-Generation Technologies to Generate Actionable Insights Faster & Advance Drug Discovery Decisions with Confidence



Taiana Maia de Oliveira
Director, Biophysics
AstraZeneca

11.00 **Accelerating High-Resolution Structural Insights with Cryo-EM to Expand Target Discovery & Shorten Drug Design Timelines**

- Achieve sub-3Å structures in weeks instead of months by leveraging optimised cryo-EM workflows, dramatically accelerating your structure-guided design cycles
- Overcome crystallisation bottlenecks for membrane proteins and large complexes, accessing structural information on targets that were previously intractable by X-ray methods and expanding your target space
- Learn strategies to manage data processing costs, storage requirements, and computational infrastructure, making cryo-EM economically viable for biotech organisations through hybrid cloud approaches and understanding true cost of ownership

Conference Day Two
Thursday 14th January, 2027



Pravin Mahajan
Associate Director, Discovery Technologies
Astex Pharmaceuticals

11.30 Unlocking Faster Drug Discovery with Cryo-EM: From Difficult Targets to Actionable Structures

- Accelerate structure-based drug discovery by implementing streamlined cryo-EM workflows that can deliver near-atomic-resolution structures in weeks, enabling faster iteration from target validation to lead optimisation
- Expand the range of druggable targets by applying cryo-EM to membrane proteins, multiprotein assemblies, and other challenging systems that are difficult or impossible to study using traditional crystallography
- Build a cost-effective cryo-EM strategy by addressing the realities of large-scale data processing, storage, and compute demands. Explore hybrid cloud and on-premise approaches, infrastructure optimisation, and total cost-of-ownership considerations for biotech teams



Kirill Pevzner
Founder & Chief Technical Officer
Protai

12.00 Unlocking Rational Design of Induced Proximity Drugs Through AI-Powered Structural Proteomics

- Demonstrating how structural proteomics and AI can reveal the architecture and dynamics of induced proximity complexes that traditional structural approaches cannot capture
- Establishing a rational design framework for molecular glues and targeted protein degraders to improve potency, selectivity, and developability
- Showcasing how AI-guided structural insights accelerated Protai's oncology pipeline, from protein complex modelling through *in vivo* efficacy and IND-enabling development

12.30 Lunch & Networking

Optimising Drug-Target Interactions to Create More Durable, Differentiated & Clinically Viable Therapeutics



Beatrice Li
Team Lead of Protein Science & Structural Biology
Confo Therapeutics

1:30 Advancing Biophysical Characterisation Technologies to Decode Challenging Membrane Targets & Increase Confidence in Drug Discovery

- Master emerging techniques for detecting small molecule binding to GPCRs and membrane proteins, overcoming the characterisation challenges that plague these high-value targets representing 30% of marketed drugs
- Learn how nanodisc technologies preserve native protein conformations and enable structural studies, improving the physiological relevance of your biophysical data and reducing false positives
- Discover strategies to stabilise dynamic GPCR conformations using conformer technology and nanobodies, enabling structure determination of specific functional states for agonist versus antagonist design



Felix Metzner
Structural Research
Boehringer Ingelheim

2.00 Structural Insights into Ligand Recognition and Modulation of a Class A GPCR

- Cryo-EM captures chemically diverse ligands bound to active and inactive states of a class A GPCR
- Comparisons across functional states reveal molecular determinants of receptor activation and inhibition
- Integrated structural and functional data guide rational ligand design

Conference Day Two
Thursday 14th January, 2027

2.30 **Afternoon Break**



Victor Guallar
ICREA Professor & Group Leader
Barcelona Supercomputing Group

3.00 **Searching Trillion-Scale Chemical Space to Accelerate Rational Discovery of Novel Molecules**

- Advancing computational approaches for searching trillion-scale synthon libraries
- Overcoming the challenges of sampling and screening complex microcycle structures
- Leveraging expanded chemical space to uncover new opportunities for structure-guided drug discovery



Christian Ottmann
Founder & Chief Executive Officer
Ambagon Therapeutics

3.30 **Engineering Molecular Glue Therapeutics Through Structure-Guided Design to Unlock Novel Targets & Accelerate Pipeline Progression**

- Leveraging structural biology and computational modelling to systematically design and optimise molecular glue therapeutics
- Unlocking novel disease pathways by targeting proteins previously considered inaccessible to conventional drug discovery approaches
- Advancing a next-generation pipeline of molecular glue candidates through data-driven discovery and preclinical validation



Beatrice Li
Team Lead of Protein Science & Structural Biology
Confo Therapeutics

4.00 **Chairs' Closing Remarks**

4.05 **Close of the Rational Based Drug Design Summit**

> "The conference included a wide range of topics and applications, the presentations were high quality and highly relevant."
>
> **CSL Seqirus, Biophysics for Drug Design Summit Attendee**

Your European Hub for Forging Meaningful Connections Across Drug Development

Rational Based Drug Design Summit EUROPE
13-14 January 2027 | Amsterdam, NE

The **inaugural Rational Based Drug Design Summit Europe** is the only meeting dedicated to uniting the scientific disciplines driving modern drug discovery, from **structural biology**, **biophysics**, and **medicinal chemistry** to **computational chemistry**, **AI**, and **molecular modelling**. Designed to accelerate safer, faster, and more efficient discovery, the summit provides a practical forum for teams seeking to expand the druggable universe, strengthen target validation, and make higher-confidence decisions earlier in development.

Whether you are a **Structural Biology & Biophysics CRO**, **Drug Discovery CRO**, **Equipment Provider**, or **AI & Computational Platform Provider**, this is your opportunity to engage directly with the scientists and decision-makers tackling today's biggest discovery challenges. Position your solutions at the centre of conversations around structure-enabled drug design, complex target characterisation, AI-driven discovery, hit identification, lead optimisation, and candidate selection while building high-value relationships with Europe's leading biopharma innovators.

Access the Leaders Shaping Europe's Drug Discovery

Connect with senior discovery leaders, computational biologists, medicinal chemists, and R&D decision-makers actively advancing next-generation therapeutics.


Accelerate Strategic Partnerships & Business Growth

Meet biopharma leaders actively investing in AI-powered discovery, computational chemistry, and next-generation R&D technologies, creating opportunities to build high-value commercial relationships.


Become the Go-To Partner for Drug Discovery Innovation

Showcase your expertise to a targeted audience of decision-makers and position your organisation as an essential partner driving the future of rational drug design.

Seniority of Attendees



Type of Companies Attending



Taken from the USA event series including structure-based design events and biophysics event

Get Involved



Akshin Gandhi
Partnerships Director
Tel: +44 20 3141 8700
Email: sponsor@hansonwade.com

Expertise Partner

NEOsphere Biotechnologies advances induced proximity drug discovery with proteome-wide insight into compound activity and selectivity. Its deep proteomic profiling of nearly 10,000 molecular glue degraders to date across 11,000 proteins has revealed 300+ molecular glue targets, and the data feeds sphereOME, a foundation dataset mapping the accessible CRBN neosubstrate space. Built on this, sphereAI predicts compound–target degradation potential, even for targets without known degron motifs, and uses reinforcement learning to propose new selective, potent degraders.

https://neospherebiotechnologies.com/

> "Great line up of engaging talks, open and friendly networking."
>
> **Vividion Therapeutics, Structure Based Drug Design Attendee**

Get Involved



Akshin Gandhi
Partnerships Director
Tel: +44 20 3141 8700
Email: sponsor@hansonwade.com

Ready to Register?

3 Easy Ways to Book

www.rational-based-drug-design-europe.com/register/

Tel: +44 20 3141 8700

Email: info@hansonwade.com

DISCOVER how leading biopharma organisations are combining AI, structural biology, biophysics, and computational chemistry to expand the druggable universe and accelerate the discovery of high-confidence therapeutic candidates

LEARN proven strategies to improve target validation, optimise hit-to-lead progression, de-risk candidate selection, and successfully translate structure-enabled discoveries into clinical success

CONNECT with senior leaders in structural biology, medicinal chemistry, computational drug design, and AI-driven discovery from organisations including Sanofi, GSK, Merck Healthcare, OMass Therapeutics, and AstraZeneca to build valuable partnerships and share best practices

Drug Developers*	Register by Friday, 13 November 2026 & Save **€330**	On the Door Price
Full Access Conference Pass	€2,119 **(Save €330)**	€2,449

Academic & Research Institutes**	Register by Friday, 13 November 2026 & Save **€330**	On the Door Price
Full Access Conference Pass	€1,819 **(Save €330)**	€2,149

Solution & Service Providers	Register by Friday, 13 November 2026 & Save **€330**	On the Door Price
Full Access Conference Pass	€3,119 **(Save €330)**	€3,449

*To qualify for the drug developer rate your company must have a public drug pipeline and not offer fee-based services. Please visit the website for full pricing options or email info@hansonwade.com

Prices exclude any applicable taxes. VAT or other indirect taxes may apply depending on event location and tax status. Eligible business customers may provide a valid VAT registration number at checkout where a reverse charge mechanism is available.

**To qualify for academic & research rate you must be full time academic. Please visit the website for full pricing options or email info@hansonwade.com

Team Discounts***

- **10% discount – 3 Attendees**
- **15% discount – 4 Attendees**
- **20% discount – 5+ Attendees**

***Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.

Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.

Contact: register@hansonwade.com



Venue

Park Plaza Victoria Amsterdam
Damrak 1, 1012 LG Amsterdam
https://www.parkplazavictoriaamsterdam.com/

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organisation can be made at any time.

Changes to Conference & Agenda: Every reasonable effort will be made to adhere to the event programme as advertised. However, it may be necessary to alter the advertised content, speakers, date, timing, format and/or location of the event. We reserve the right to amend or cancel any event at any time. Hanson Wade Conferences Limited is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Hanson Wade Conferences Limited, Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH, United Kingdom